1. Yamaoka Y. Revolution of Helicobacter pylori treatment. J Gastroenterol Hepatol. 2024 Jun;39(6):1016-1026. doi: 10.1111/jgh.16526.
2. Tourrette E, Torres RC, Svensson SL, Matsumoto T, Miftahussurur M, Fauzia KA, Alfaray RI, Vilaichone RK, Tuan VP; Helicobacter Genomics Consortium; Wang D, Yadegar A, Olsson LM, Zhou Z, Yamaoka Y, Thorell K, Falush D. An ancient ecospecies of Helicobacter pylori. Nature. 2024 Nov;635(8037):178-185. doi: 10.1038/s41586-024-07991-z.
3. Fauzia KA, Effendi WI, Alfaray RI, Malaty HM, Yamaoka Y, Mifthussurur M. Molecular Mechanisms of Biofilm Formation in Helicobacter pylori. Antibiotics (Basel). 2024 Oct 16;13(10):976. doi: 10.3390/antibiotics13100976.
4. Do TMP, Tran THT, Nguyen VT, Chu TPM, Nguyen L, Nguyen KT, Hoang TBN, Phuong ALH, Yamaoka Y, Olson L, Nguyen TVH. Efficacy of Bismuth Quadruple Therapy in the Treatment of Helicobacter pylori-Infected Peptic Ulcer Children in Vietnam. Helicobacter. 2024 Nov-Dec;29(6):e13149. doi: 10.1111/hel.13149.
5. Subsomwong P, Asano K, Akada J, Matsumoto T, Nakane A, Yamaoka Y. Proteomic Profiling of Extracellular Vesicles Reveals Potential Biomarkers for Helicobacter pylori Infection and Gastric Cancer. Helicobacter. 2025 Mar-Apr;30(2):e70022. doi: 10.1111/hel.70022.
6. Fauzia KA, Rathnayake J, Doohan D, Lamawansa MD, Alfaray RI, Batsaikhan S, Phuc BH, Waskito LA, Tuan VP, Kabamba ET, Ansari S, Matsumoto T, Akada J, Matsuhisa T, Yamaoka Y. Beyond Low Prevalence: Exploring Antibiotic Resistance and Virulence Profiles in Sri Lankan Helicobacter pylori with Comparative Genomics. Microorganisms. 2025 Feb 14;13(2):420. doi: 10.3390/microorganisms13020420.
7. Amalia R, Miftahussurur M, Syam AF, Uchida T, Alfaray RI, Fauzia KA, Rezkitha YAA, Akada J, Matsumoto T, Yamaoka Y. Parietal Cell Antibody Levels Among Chronic Gastritis Patients in a Country With Low Helicobacter pylori Infection: Epidemiology, Histopathological Features, and H. pylori Infection. Helicobacter. 2025 Mar-Apr;30(2):e70035. doi: 10.1111/hel.70035.
8. Tungtrongchitr N, Bongkotvirawan P, Ratana-Amornpin S, Siramolpiwat S, Eiamsitrakoon T, Gamnarai P, Wongcha-Um A, Yamaoka Y, Pawa KK, Vilaichone RK. Fourteen-day vonoprazan-based bismuth quadruple therapy for H. pylori eradication in an area with high clarithromycin and levofloxacin resistance: a prospective randomized study (VQ-HP trial). Sci Rep. 2024 Apr 18;14(1):8986. doi: 10.1038/s41598-024-59621-3.
9. Savitri CMA, Fauzia KA, Alfaray RI, Aftab H, Syam AF, Lubis M, Yamaoka Y, Miftahussurur M. Opportunities for Helicobacter pylori Eradication beyond Conventional Antibiotics. Microorganisms. 2024 Sep 30;12(10):1986. doi: 10.3390/microorganisms12101986.
10. Aumpan N, Gamnarai P, Wongcha-Um A, Miftahussurur M, Yamaoka Y, Vilaichone RK. The use of real-world evidence to generate cost analysis of antibiotic susceptibility testing (AST) in patients with Helicobacter pylori treatment failure in Thailand: A large population-based study. Heliyon. 2024 Oct 10;10(21):e39189. doi: 10.1016/j.heliyon.2024.e39189.